Your session is about to expire
← Back to Search
Effervescent Calcium-Magnesium Citrate for End-Stage Renal Disease
Study Summary
This trial will explore whether effervescent calcium magnesium citrate (EffCaMgCit) can help people with end stage renal disease on hemodialysis by reducing the formation of calciprotein particles (CPP), which can cause heart and artery problems.
Eligibility Criteria
Inclusion Criteria
You may be eligible if you check “Yes” for the criteria belowTimeline
Treatment Details
Study Objectives
Outcome measures can provide a clearer picture of what you can expect from a treatment.Trial Design
Find a Location
Who is running the clinical trial?
Media Library
- Your blood test shows a high level of magnesium.I am not taking steroids or aluminum-based antacids.I am over 21, on hemodialysis, and have stage V chronic kidney disease.I am taking medication for osteoporosis, chronic kidney disease, high blood pressure, diabetes, or hormone therapy.People with Type II diabetes and high blood pressure can participate.I do not have bowel disease, high calcium, or low phosphate levels.
- Group 1: EffCaMgCit
- Group 2: CaAcS
- No Placebo-Only Group - All patients enrolled in this study will receive some form of active treatment.
- Screening: It may take up to 3 Weeks to process to see if you qualify in this trial.
- Treatment: The duration you will receive the treatment varies.
- Follow Ups: You may be asked to continue sharing information regarding the trial for 6 Months after you stop receiving the treatment.
Frequently Asked Questions
Are there still opportunities to enroll in this research project?
"Yes, this study is still looking for participants and was most recently updated on February 9th, 2022. The original posting date was January 22nd, 2017."
Does this research only include young adults in their twenties?
"To be eligible for this particular trial, patients must be between 18-99 years old. However, there are other ongoing trials for patients that are under 18 and ones for patients that are over 65."
How many research subjects are involved in this trial?
"Yes, the trial is still recruiting patients according to the information on clinicaltrials.gov. This specific study was first posted on 1/22/2017 and was edited on 2/9/2022. The research team is looking for 225 individuals total from 1 site."
What are the requirements to sign up for this clinical trial?
"This study is currently enrolling 225 patients with chronic kidney disease. To be eligible, patients must be between 18 and 99 years old. In addition, the following criteria must be met: Adult subjects (> 21 years of age, any cause of CKD) of either gender of any ethnicity with CKD Stage V on hemodialysis will be recruited. Patients with Type II diabetes and hypertension will be allowed. Treatment with drugs for management of osteoporosis (bisphosphonate, teriparatide, or denosumab) or for chronic kidney disease, customary drugs for hypertension or diabetes, and exogenous estrogen or"
Share this study with friends
Copy Link
Messenger